N/A
Completed N=426
Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray
Source: ClinicalTrials.gov NCT05146206 ↗Enrolled (actual)
426
Serious AEs
—
Results posted
Apr 2024
Primary outcomePrimary: Overall Best-Worst Scaling Task Index Score (Treatment Satisfaction Index Score) — 68.26; 62.78 units on a scale — p=<.001
Summary
The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Best-Worst Scaling Task Index Score (Treatment Satisfaction Index Score) |
68.26; 62.78 | <.001 sig |
| SECONDARY Rescaled Scores From Best-Worst Scaling Task |
6.12; 4.66; 5.84; 4.21; 6.31; 5.55 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study:
- Patients above 18 years old
- Fluent in English
- Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and currently using treatment
- Willing and able to provide consent to participate
Exclusion Criteria
- Have reported a loss of taste and/or smell related to COVID-19 (or other medical condition)
- Are employed by a pharmaceutical company (to avoid conflict of interest)
- Are employed by a vaccine company (to avoid conflict of interest)
- Do not have access to the internet (to ensure validity of the data)
- Are unable to read and understand English (to ensure validity of the data)
Data sourced from ClinicalTrials.gov (NCT05146206). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.